<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387942</url>
  </required_header>
  <id_info>
    <org_study_id>20K012-001</org_study_id>
    <nct_id>NCT04387942</nct_id>
  </id_info>
  <brief_title>The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura</brief_title>
  <acronym>HSP</acronym>
  <official_title>The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children
      with Henoch-schönlein purpura.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a single center, open-label, prospective study that routinely
      administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory
      parameters to explore its efficacy and to observe changes in immune cell subsets and
      cytokines.For all patients,rhIL-2(500,000 unit per square meter) infusions seven
      days;recurrent patients were applied again for 7 days;patients who were diagnosed HSPN were
      treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>group A:patients were treated with IL-2.group B:patients were not treated with IL-2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of immunological responses</measure>
    <time_frame>day 0,day 7</time_frame>
    <description>Enumeration of the number of subjects with a change in the absolute number of immune cells and serum cytokines in the peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The value of serum immunoglobulins and complements</measure>
    <time_frame>day 0,day 7,3 month,6 month</time_frame>
    <description>Laboratory measures were detected, including,serum total IgE, serum Ig A,serum IgG,serum IgM,C3 and C4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event,drug-induced liver and kidney damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Purpura, Schoenlein-Henoch</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients were treated with IL-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.</description>
    <arm_group_label>Recombinant Human Interleukin-2</arm_group_label>
    <other_name>Recombinant Human Interleukin-2 for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age &lt;18 years old

          2. meet the EULAR/PRINTO/PRES for the diagnosis of HSP

          3. HIV negative;Negative for HBV and HCV.

        Exclusion Criteria:

          1. heart failure (cardiac function ≥ grade III NYHA)

          2. liver insufficiency (upper limit of normal range of transaminase &gt; 2 times)

          3. renal insufficiency (creatinine clearance ≤30ml/min)

          4. acute or severe infections such as bacteremia and sepsis

          5. malignant tumor

          6. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the
             last 1 month

          7. mental disorders or any other chronic illness or substance abuse may interfere with
             the ability to comply with agreements or provide information

          8. Intestinal ischemia or perforated gastrointestinal bleeding requires surgery

          9. Inability to comply with IL-2 treatment regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang si rui, MD and PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang si rui, MD and PhD</last_name>
    <phone>13500889222</phone>
    <email>sryang@jlu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sirui Yang</name>
      <address>
        <city>Changchun</city>
        <state>Changchun/JiLin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirui Yang</last_name>
      <phone>86-13500889222</phone>
      <email>sryang@jlu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>St John J, Vedak P, Garza-Mayers AC, Hoang MP, Nigwekar SU, Kroshinsky D. Location of skin lesions in Henoch-Schönlein purpura and its association with significant renal involvement. J Am Acad Dermatol. 2018 Jan;78(1):115-120. doi: 10.1016/j.jaad.2017.04.1122.</citation>
    <PMID>29241772</PMID>
  </reference>
  <reference>
    <citation>Jen HY, Chuang YH, Lin SC, Chiang BL, Yang YH. Increased serum interleukin-17 and peripheral Th17 cells in children with acute Henoch-Schönlein purpura. Pediatr Allergy Immunol. 2011 Dec;22(8):862-8. doi: 10.1111/j.1399-3038.2011.01198.x. Epub 2011 Sep 19.</citation>
    <PMID>21929599</PMID>
  </reference>
  <reference>
    <citation>Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142-51. Epub 2005 Oct 16. Erratum in: Nat Immunol. 2006 Apr;7(4):427.</citation>
    <PMID>16227984</PMID>
  </reference>
  <reference>
    <citation>Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol. 2018 Apr 26;36:411-433. doi: 10.1146/annurev-immunol-042617-053352. Review.</citation>
    <PMID>29677473</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura, Schoenlein-Henoch</mesh_term>
    <mesh_term>Purpura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

